PTGS2 and pulmonary arterial hypertension: Our preclinical studies demonstrate elevated eicosanoid levels in the lung and heart tissue samples from rats subjected to the SuHx protocol and that treatment with a COX-2 inhibitor did not worsen the PAH, while diethylcarbamazine impacted the pulmonary vascular disease in this model of severe PAH.